HealMed Research Team
5 min
Large language models achieve impressive results on English medical benchmarks, but it remains unclear whether these capabilities transfer reliably to other languages. Many existing multilingual medical benchmarks rely on unverified machine translations, which can distort medical terminology and syntax. This study investigates the true multilingual competence of 14 prominent language models using HealMed, a meticulously expert-reviewed medical benchmark developed across nine languages.
HealMed contains 1,000 examples per language drawn from nine source datasets, covering multiple-choice question answering (MCQA), natural language inference (NLI), and open-ended question answering (QA). The evaluated languages include English, German, Spanish, Portuguese, Japanese, Chinese, Thai, Swahili, and Zulu. The benchmark construction involved 23 medical experts across nine countries who performed a rigorous two-stage review of machine-translated instances, scoring and revising them for accuracy, fluency, and completeness.
The evaluation demonstrates that the strongest proprietary models combine high accuracy with remarkable cross-language stability, whereas non-proprietary open-source and medically specialized models experience severe performance drops in lower-resource languages. Crucially, medical specialization alone does not guarantee multilingual robustness. Performance losses were heavily concentrated in Swahili and Zulu, driven by major terminology and fluency issues. Furthermore, paired comparisons against unrevised machine-translated data show that expert review substantially alters measured performance, proving that raw machine translation introduces measurement bias in cross-lingual evaluation.
We present HealMed, an expert-reviewed benchmark for multilingual evaluation of large language models in medicine. HealMed contains 1,000 examples in each of nine languages, drawn from nine datasets and covering three task formats: MCQA, NLI and open-ended QA. The benchmark was developed over two years by 23 physicians and medical experts based across nine countries and regions. Each translation was evaluated and revised by two experts fluent in English and the corresponding target language. On HealMed, performance declined most in low-resource languages, although the size of the gap varied markedly across languages and models. The strongest proprietary models were the most stable across languages, whereas many open-source and medically specialized models showed larger and less consistent gaps. Medical specialization alone did not ensure multilingual robustness. Furthermore, expert revision could either raise or lower measured performance, indicating that translation quality materially affects cross-language evaluation results.
Alex: That's a meaningful constraint on how we think about deploying medically fine-tuned models globally.
Sam: It is. And it connects directly to the evaluation methodology. The expert-reviewed data often yielded meaningfully different performance estimates than the raw translated versions of the same items. That's the empirical demonstration that translation quality is a load-bearing variable in the evaluation pipeline — not a nuisance parameter you can ignore.
Alex: How did they handle open-ended clinical responses, where there isn't a single correct answer to score against?
Sam: They used an LLM-as-judge protocol. The judge model receives the target language, the expert-verified question, the reference answer, and the model's output, then scores the response on dimensions including clinical consensus and safety. It's a reasonable approach for free-text evaluation, but it introduces its own validity question — how well-calibrated is the judge across languages, particularly for the lower-resource ones where the benchmark is doing its most important work? The paper doesn't fully resolve that, and a careful referee would push on it.
Alex: There's a potential circularity risk — you're using a language model to evaluate outputs in languages where language models are known to be weaker.
Sam: That's the live concern. It doesn't invalidate the approach, but it does mean the open-ended evaluation results should be read with more caution than the multiple-choice items, where scoring is deterministic.
Alex: Stepping back — what's the practical upshot for someone building or benchmarking these systems?
Sam: If you're evaluating a medical AI system for multilingual deployment and you're relying on machine-translated benchmarks, you are measuring something that includes translation quality as an uncontrolled variable. Your performance estimates are biased in ways that vary by language and task, and you can't correct for it post hoc. HealMed is making the case that expert-reviewed, natively-curated evaluation data isn't a luxury — it's a prerequisite for knowing where these models actually stand in a clinical setting.
Alex: And given the stakes of clinical deployment, that's a methodological argument worth taking seriously. Thanks for listening to ResearchPod.